SEC Tracker
Get the app
CATX · XBRL financial data

Perspective Therapeutics financial statements, every quarter

The same tables from 13 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (CATX's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue2,185———————————
Cost of goods and services sold1,447———————————
Gross profit738———————————
Research and development5,7216,080*7,4529,27512,02812,883*14,33216,62020,33932,924*21,37221,544
General and administrative4,6964,272*5,8785,5146,9758,246*7,8427,7097,7316,951*6,9857,795
Total operating expenses11,2727,767*13,33014,78919,00345,218*22,17424,32928,07039,875*28,35729,339
Operating income (loss)(10,534)(7,806)*(13,005)(14,263)(18,634)(44,984)*(21,832)(24,039)(27,861)(39,832)*(28,281)(29,258)
Interest income20462*1,2113,0763,5812,647*2,3842,1591,9571,614*2,1972,347
Interest expense1424*——————————
Income tax expense (benefit)07,849*———year only———year only——
Net income (loss)(10,356)(24,675)*(12,284)(11,704)(15,122)(40,169)*(18,177)(21,485)(25,969)(37,490)*(26,189)(26,786)
Earnings per share, basic‡ USD per share(0.40)(0.90)*(0.20)(0.18)(0.21)—(0.25)(0.29)(0.35)(0.50)*(0.25)(0.22)
Earnings per share, diluted‡ USD per share(0.37)—(0.20)(0.18)(0.21)—(0.25)(0.29)(0.35)(0.50)*(0.25)(0.22)
Weighted average shares, basic‡ thousands of shares28,05628,072*49,51066,64870,62970,775*72,35774,23574,29674,337*103,604120,651
Weighted average shares, diluted‡ thousands of shares28,05528,071*49,51066,64870,62970,775*72,35774,23574,29674,337*103,604120,651
  • ‡ Per-share figures and share counts are adjusted for the 1-for-10 stock split (June 2024); filings made before it reported them unadjusted.

Balance sheet

CSV

Fiscal quarters (CATX's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents17,9839,238142,117252,004226,44361,58044,40628,84926,76230,62953,97248,488
Short-term investments0038,53140,86541,404165,336167,296162,729147,375114,108216,957188,388
Accounts receivable1,7311,16599914221711678225179658269
Inventory1,013———————————
Prepaid and other current assets9611,1331,2871,2262,1084,1283,9624,1554,1843,6464,3654,378
Total current assets21,68816,837188,200294,237270,172231,160215,742195,958178,500148,389275,352241,523
Property and equipment, net7,0125,57614,30214,74743,79257,32161,24762,59964,35176,59792,483107,797
Right-of-use asset1,5297471,0582,0192,4332,2151,9941,7671,5361,5002,4442,196
Goodwill27,31924,06224,06224,06224,0620——————
Total assets110,51897,891278,286385,919391,153341,101329,349310,725294,825266,972410,769392,025
Total current liabilities8,11515,66414,50310,61028,14318,23012,67912,98620,61828,67931,48636,544
Lease liability, non-current1,2767801,0371,4501,6761,4281,1741,0719711,0051,5521,269
Total liabilities11,74822,71248,39544,92262,68250,43344,70445,03352,60959,94163,33168,162
Accumulated deficit(127,765)(152,440)(164,724)(176,428)(191,550)(231,719)(249,896)(271,381)(297,350)(334,840)(361,029)(387,815)
Total stockholders' equity98,77075,179229,891340,997328,471290,668284,645265,692242,216207,031347,438323,863
Total liabilities and equity110,51897,891278,286385,919391,153341,101329,349310,725294,825266,972410,769392,025
Common shares outstanding (cover page)‡ thousands of shares28,05758,69262,26367,42867,58874,05274,22874,26374,338113,933114,046114,152
  • ‡ Per-share figures and share counts are adjusted for the 1-for-10 stock split (June 2024); filings made before it reported them unadjusted.

Cash flows

CSV

Fiscal quarters (CATX's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(10,356)(24,675)*(12,284)(11,704)(15,122)(40,169)*(18,177)(21,485)(25,969)(37,490)*(26,189)(26,786)
Stock-based compensation451*720*656719*1,952*2,060*2,0982,403*2,156*2,309*2,5533,046*
Net cash from operating activities(10,110)*(9,008)*13,848(8,902)*3,366*(26,606)*(21,582)(19,953)*(16,292)*(24,657)*(31,468)(20,650)*
Purchases of property and equipment227*89*9,0721,015*29,713*14,614*4,6561,026*1,992*5,075*6,85814,195*
Net cash from investing activities(227)*(89)*(47,297)(3,295)*(29,737)*(138,602)*(5,565)4,264*13,992*28,537*(109,553)15,019*
Proceeds from issuing common stock—year only———year only——————
Net cash from financing activities1*352*166,328122,084*628*345*9,973132*213*(13)*164,364147*
Net change in cash(10,336)*(8,745)*132,879109,887*(25,743)*(164,863)*(17,174)(15,557)*(2,087)*3,867*23,343(5,484)*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Perspective Therapeutics48,488not reported(20,650)*114.2M11.5 quarters 10-QJun 30, 2026
Rocket Pharmaceuticals224,5070(39,613)*109.8M7.2 quarters 10-QJun 30, 2026
Natures Sunshine Products82,503116,985835*17.6M— 10-QJun 30, 2026
Tvardi Therapeutics15,765not reported(9,228)*13.3M1.7 quarters 10-QJun 30, 2026
SELLAS Life Sciences Group138,343not reported(7,588)*201.9M18.2 quarters 10-QJun 30, 2026
Precigen16,32954,978(17,809)*358.0M2.1 quarters 10-QJun 30, 2026
Silence Therapeutics72,05401,518*141.7M— 10-QJun 30, 2026
Cardiff Oncology9,197104(11,765)*77.8M2.9 quarters 10-QJun 30, 2026
Rezolute10,615not reported(13,146)*96.7M8.2 quarters 10-KJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.